GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (OTCPK:AWHL) » Definitions » Equity-to-Asset

AWHL (Aspira Womens Health) Equity-to-Asset : -0.47 (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aspira Womens Health Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aspira Womens Health's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $-2.56 Mil. Aspira Womens Health's Total Assets for the quarter that ended in Dec. 2024 was $5.49 Mil. Therefore, Aspira Womens Health's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was -0.47.

The historical rank and industry rank for Aspira Womens Health's Equity-to-Asset or its related term are showing as below:

AWHL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.47   Med: 0.48   Max: 0.84
Current: -0.47

During the past 13 years, the highest Equity to Asset Ratio of Aspira Womens Health was 0.84. The lowest was -0.47. And the median was 0.48.

AWHL's Equity-to-Asset is ranked worse than
93.81% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.63 vs AWHL: -0.47

Aspira Womens Health Equity-to-Asset Historical Data

The historical data trend for Aspira Womens Health's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Equity-to-Asset Chart

Aspira Womens Health Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.73 0.40 -0.38 -0.47

Aspira Womens Health Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.38 -0.19 -0.94 -0.53 -0.47

Competitive Comparison of Aspira Womens Health's Equity-to-Asset

For the Diagnostics & Research subindustry, Aspira Womens Health's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspira Womens Health's Equity-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Equity-to-Asset falls into.


;
;

Aspira Womens Health Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Aspira Womens Health's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=-2.563/5.491
=-0.47

Aspira Womens Health's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=-2.563/5.491
=-0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aspira Womens Health  (OTCPK:AWHL) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Aspira Womens Health Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspira Womens Health Business Description

Traded in Other Exchanges
Address
12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
Executives
Nicole Sandford director 12117 BEE CAVES RD BLDG 3, STE 100, AUSTIN TX 78738
Minh Hoang Merchant officer: General Counsel & Secretary 1210 AVONDALE ROAD, HILLSBOROUGH CA 94010
Torsten Hombeck officer: Chief Financial Officer 529 W 42ND ST #6V, NEW YORK NY 10036
Celeste Rachelle Fralick director 2801 MESA ROAD, LUBBOCK TX 79403
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Stefanie L. Cavanaugh director 1120 S CAPITAL OF TX HWY, BLDG 1, STE 300, AUSTIN TX 78746
Ellen O'connor Vos director C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Ryan Thinh Phan officer: CSO & COO 327 CARLTON AVE, LOS GATOS CA 95032
Jannie Prestridge Herchuk director 6331 LAVENDALE AVE, DALLAS TX 75230
Winfred Parnell director 6734 TALMADGE LANE, DALLAS TX 75230
Marlene Mclennan officer: Interim Chief Financial Office 400 SOUTH AUSTRALIAN AVENUE, SUITE 800, WEST PALM BEACH FL 33401
Ruby Sharma director 24 ARNOLD DRIVE, PRINCETON JCT. NJ 08550
Robert D Auerbach director C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Valerie Barber Palmieri director, officer: President and CEO 63 INDIAN LEDGE RD., MONROE CT 06468